Currently Viewing:
Newsroom
Currently Reading
Study Finds 74% Long-Term Survival Rate for Patients With Myelofibrosis
February 22, 2019 – Samantha DiGrande
FDA Approves the First Drug Specifically Indicated for aTTP
February 11, 2019 – Kelly Davio
Thymectomy Plus Prednisone Shows Benefit in Patients With Nonthymomatous Myasthenia Gravis
February 10, 2019 – David Bai, PharmD
New Predictive Model Developed for Leukemic Transformation in Primary Myelofibrosis
February 04, 2019 – Kelly Davio
Orphan Drugs Have Lower Drug Development Costs Compared With Nonorphan Drugs
February 03, 2019 – David Bai, PharmD
ASCO Names "Progress in Treating Rare Cancers" as the Advance of the Year
January 31, 2019 – Jaime Rosenberg
Defective Toll-Like Receptor Regulation May Predispose Individuals to MPNs
January 28, 2019 – Kelly Davio
Healthcare Costs for Mitochondrial Disease Are Comparable to Those for ALS and MS
January 24, 2019 – David Bai, PharmD
FDA Revises Draft Guidance on Developing Drugs for Rare Diseases
January 21, 2019 – Kelly Davio

Study Finds 74% Long-Term Survival Rate for Patients With Myelofibrosis

Samantha DiGrande
The only curative treatment for myelofibrosis (MF) continues to be allogeneic hematopoietic stem cell transplant (HSCT). Occasionally, adverse events posttransplantation can occur and usually present within the first 2 years after posttransplant. Researchers recently sought to analyze the outcome of 2-year disease-free survivors in a systematic review published in Haematologica.
The only curative treatment for myelofibrosis (MF) continues to be allogeneic hematopoietic stem cell transplant (HSCT). Occasionally, adverse events posttransplantation can occur and usually present within the first 2 years after posttransplant. Researchers recently sought to analyze the outcome of 2-year disease-free survivors in a systematic review published in Haematologica.

In total 2459 patients were identified through the Human Mortality Database who had received a first HSCT between January 1995 and December 2014 for primary or secondary MF. Of this, 1055 patients had been reported alive and disease free 2 years after HSCT.

The entire cohort (N = 2459) had an overall survival rate at 10 years of 41% (95% CI: 39-44) and a disease-free survival rate of 32% (95% CI: 30-35). In the 1055 patients who were categorized as “long-term survivors,” 166 deaths were reported within 10 years after HSCT. For all time periods, the most common cause of death was relapse of MF, followed by graft versus host disease, and infection. Of note, infection was most common between 2- and 5-years posttransplant. This high risk of infection “should be taken into account in long-term monitoring strategies and highlights the importance of appropriate anti-infective prophylaxis,” wrote the authors.

Furthermore, secondary cancers occurred in 34 patients before reaching 2 years after HSCT, and 87 patients after 2 years. The most frequent cancer was solid tumor, acute leukemia or myelodysplastic syndrome, and lymphoma.

Overall, the authors found that results show the survival rate 10 years after transplantation in these 2-year survivors is 74%. Patients with MF that reach the 2-year mark post-HSCT, particularly younger and female patients, have “good survival,” according to study authors. The investigators recommended that patients should receive follow up for life, and particularly, severe late complications and late relapses should be monitored in order to reduce life-threatening complications.

References

Robin M, de Weede LC, Wolschke C, et al. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis [published online February 2019]. Haematol. doi: 10.3324/haematol.2018.205211.

Related Articles

Evolution of Myelofibrosis and Efficacy & Toxicity of Therapy
New Predictive Model Developed for Leukemic Transformation in Primary Myelofibrosis
Future of Therapy and Final Thoughts on Myelofibrosis
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up